Hydroxychloroquine immediate release tablets:  
Formulation and evaluation of a solid dosage form

Tomaž Einfalt¹, Pascal Detampel¹, Daniel Häussinger², Jens Casper¹, Christoph Meier³, Maxim Puchkov¹, Jörg Huwyler¹

¹Department of Pharmaceutical Technology, University of Basel, Klingelbergstrasse. 50, 4056 Basel, Switzerland;
²Department of Chemistry, University of Basel, St. Johannis-Ring 19, 4056 Basel, Switzerland;
³Department of Clinical Pharmacy, University of Basel, Klingelbergstrasse. 50, 4056 Basel, Switzerland;

*Correspondence:
Prof. Dr. Jörg Huwyler
University of Basel
Division of Pharmaceutical Technology
Klingelbergstrasse 50, 4056 Basel, Switzerland
Tel: +41 61 207 15 13; E-mail: joerg.huwyler@unibas.ch
Abstract

Hydroxychloroquine (HCQ) is a quinoline derivate used for the treatment of malaria and rheumatoid disorders. During early phases of the SARS-CoV2 (COVID-19) pandemic, preliminary and later not substantiated reports suggested that HCQ might benefit COVID-19 patients. This had sparked a worldwide and rapidly rising demand for HCQ drug products. Consequently, patients with pre-existing rheumatic diseases in Switzerland were confronted with an acute drug shortage.

We have therefore designed, produced and characterized a generic HCQ drug formulation. The proposed HCQ formulation can be manufactured by using a minimal number of operation steps (mixing, wet granulation, sieving, blending, compression) and readily available pharmaceutical excipients.

HCQ tablets were manufactured by granulation of the active pharmaceutical ingredient (API), blending with the external phase and compaction using a non instrumented single punch tablet press. Analytics and identification of the API was performed by a combination of NMR, ESI-MS, FTIR and HPLC. HCQ tablets met the quality criteria for an immediate release HCQ dosage form.

We hope that free access to non-proprietary protocols covering analytical procedures, formulation design, and manufacturing instructions for HCQ tablets will help to bridge existing and future supply chain gaps.

Keywords: hydroxychloroquine, tablet, immediate release, solid dosage form
**Abbreviations**

API, Active Pharmaceutical Ingredient; BCS, Biopharmaceutics Classification System; COVID-19, Coronavirus disease; COSY, Correlated Spectroscopy; EDQM, European Directorate for the Quality of Medicines; ESI-MS, Electrospray Ionization Mass Spectroscopy; Eur. Pharm., European Pharmacopoeia; FDA, Food and Drug Administration; FTIR, Fourier-Transform Infrared Spectroscopy; HPLC, High Performance Liquid Chromatography; HP, Hydroxypropylcellulose; HCQ, Hydroxychloroquine; HSQC, Heteronuclear Single Quantum Coherence; NOSY, Nuclear Overhauser Effect Spectroscopy; NMR, Nuclear Magnetic Resonance; UPLC, Ultra Performance Liquid Chromatography; USP, United States Pharmacopoeia; UV-Vis, Ultraviolet–Visible spectroscopy.
Introduction

Hydroxychloroquine (HCQ) and chloroquine are clinically used as antimalarial drugs (1,2) and to treat rheumatoid arthritis, systemic lupus erythematosus, and other inflammatory rheumatic diseases (3). HCQ was first synthesized in 1950 and made available as a drug in 1955. Hydroxychloroquine sulfate used in the present study is classified as a BCS-3 drug, with high solubility (about 200 mg/mL in water) and absorption in the upper GI tract. The oral bioavailability is in the range of 75% (4). Due to accumulation in the lysosomal compartment (1), HCQ has a high volume of distribution of approximately 30 L/kg (5) leading to a long half-life in the circulation (~30 days). Indeed, it has been estimated that it takes 4 month of daily dosing to achieve 90% of steady-state blood concentrations (4). In this study, single oral administration of HCQ sulfate (200 mg) led to mean maximum plasma concentrations of 244 ng/mL within 2 to 4.5 hours. This corresponds to 25% of steady-state blood concentrations after chronic administration. Side effects associated with HCQ administration include gastrointestinal and abdominal discomfort. In rare cases, drug induced cardiotoxicity, QT prolongation and myopathy were observed (6).

HCQ gained global attention as a potential treatment of COVID-19 infections (7) based on promising but preliminary reports. Unfortunately, subsequent multicenter randomized trials found no differences in outcomes as compared to placebo (8). The initial hype nevertheless caused a rapidly increasing demand. In Switzerland, stocks of Plaquenil® and the co-marketing drug Zentiva® (i.e. coated tablets containing 200 mg of HCQ) were sold out and patients suffering from pre-existing chronic diseases were confronted with an acute drug shortage. While tablets (i.e. the commonly prescribed oral dosage form) were scarce, the active pharmaceutical ingredient HCQ sulfate was still available in Switzerland and could be obtained in sufficient quantity.

In view of current and potential future HCQ drug shortages worldwide, we therefore decided to design a generic tablet formulation of HCQ. It was our aim to define a simple and robust process, which should rely on minimal unit of operation manufacturing steps and readily available excipients. Considering product-specific FDA guidances, hydroxychloroquine sulfate based formulations can request bioequivalence waivers for immediate release formulations.
(9). Therefore, our formulation is designed to be a generic alternative to the FDA approved Plaquenil®. In response to the COVID-19 crisis, non-proprietary analytical and manufacturing protocols are hereby provided.

Materials and Methods

Materials
Hydroxychloroquine sulphate (HCQ) was purchased from SCI Pharmtech (Taoyuan City, Taiwan). Calcium hydrogen phosphate, anhydrous (Emcompress) was donated by Glatt AG (Binzen, Germany). Hydroxypropyl cellulose low viscosity (Disso HPC-L, Nippon Soda Co. Ltd, Tokyo, Japan) was received as a gift from Glatt AG (Binzen, Germany). Crosscarmellose sodium NF (Ac-Di-Sol SD-711 NF) was purchased from FMC International (Philadelphia, PA). Magnesium stearate was purchased from Haensler AG (Herisau, Switzerland). Colloidal silica (Aerosil Pharma 200 VV) was purchased from Evonik Industries (Essen, Germany).

Analytical methods
NMR spectra were recorded on a Bruker Avance III spectrometer (Billerica, MA) operating at 600.13 MHz proton frequency, equipped with a direct observe BBFO smart probe with self-shielded z-gradient. HCQ samples were dissolved in D$_2$O with internal referencing to TSP-d$_4$ (δ$^1$H: −0.083 ppm, δ$^{13}$C: −2.74 ppm (10); the final tablet was finely powdered using an agate mortar and pestle, 17.63 mg of the resulting powder were suspended in 1.0 mL of D$_2$O, homogenized on a vortex mixer, centrifuged at 13'000 rpm for 5 min and the supernatant was carefully collected for NMR and ESI-MS analyses. HPC samples were dissolved in acetone-d$_6$ using residual solvent signals as references (δ$^1$H: 2.05 ppm, δ$^{13}$C: 29.92 ppm). Spectra were recorded at 298 K and the temperature was calibrated using a methanol standard showing accuracy within +/- 0.2 K. The chemical structure of HCQ, numbering of carbon atoms, and a summary of NMR chemical shifts are provided in Figure 1.

Infrared (IR) spectra were recorded on a Shimadzu FTIR Tracer 100 spectrometer (Shimadzu, Kyoto, Japan) with a diamond anvil. IR spectra were semi-automatically baseline corrected using a multipoint algorithm. Absorption bands are given in wave numbers ν ~ [cm$^{-1}$].

Einfalt et al. (Preparation of hydroxychloroquine tablets)
UV-VIS spectrum was recorded with UPLC Shimadzu Nexera, SPD-M30A PDA model. Start wavelength was set to 190 nm, end wavelength was set to 700 nm, slit width was 8 nm.

ESI-MS spectra were recorded on a Bruker maXis 4G QTOF ESI mass spectrometer. Spectra were recorded in the positive ion mode using pure API or a finely powdered tablet.

Figure 1. Chemical structure, numbering of carbon atoms, and NMR chemical shifts of hydroxychloroquine (HCQ). Hydroxychloroquine sulfate (C_{18}H_{26}ClN_{3}O \cdot H_{2}SO_{4}) used in the present study has a MW of 433.95 g/mol. $^1$H-NMR spectra were recorded in D$_2$O at 298 K and 600.1 MHz (black numbers). $^{13}$C($^1$H)-NMR spectra were recorded in D$_2$O at 298 K and 150.9 MHz (red numbers).

Preparation of tablets

HCQ, calcium hydrogen phosphate, and HPC-L were weighed and pre-mixed in a Mycromix high shear mixer (Oystar Hüttlin, Schopfheim, Germany) at a mixer and chopper speed of 116 rpm and 1420 rpm, respectively, for 5 min. Subsequently, the powder was wet granulated by adding deionized water to the granulation vessel at mixer and chopper speed up to 160 rpm and 2000 rpm, respectively, for 28 min. The obtained granulate of HCQ were dried at 80°C for 25 min and milled with a screen mill (Fitz mill model L1A, Fitz Patrick, Waterloo, Canada). Sieved (1.25 mm) and milled granules were blended together. The external phase of crosscarmellose sodium, colloidal silica, and finally magnesium stearate was added by
subsequent mixing of each component in a Turbula powder blender T2C (W.A. Bachofen, Muttenz, Switzerland) for 5 minutes each. Complete formulation of the developed HCQ tablets is shown in Table 1.

Table 1. Composition of the HCQ tablets.

<table>
<thead>
<tr>
<th>Component</th>
<th>Amount per tablet</th>
<th>Amount per batch</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxychloroquine sulphate</td>
<td>200 mg 68.97 %, w/w</td>
<td>1000 g</td>
</tr>
<tr>
<td>Calcium hydrogen phosphate, dihydrate</td>
<td>62 mg 21.38 %, w/w</td>
<td>310 g</td>
</tr>
<tr>
<td>HPC-L</td>
<td>11 mg 3.79 %, w/w</td>
<td>55 g</td>
</tr>
<tr>
<td>Crosscarmellose sodium</td>
<td>13 mg 4.48 %, w/w</td>
<td>65 g</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>3 mg 1.03 %, w/w</td>
<td>15 g</td>
</tr>
<tr>
<td>Colloidal silica</td>
<td>1 mg 0.34 %, w/w</td>
<td>5 g</td>
</tr>
<tr>
<td>Tablet weight</td>
<td>290 mg 100 %, w/w</td>
<td></td>
</tr>
<tr>
<td>Total batch size</td>
<td></td>
<td>1450 g</td>
</tr>
</tbody>
</table>

The resulting granulate was compressed using a single punch press (Korsch EK0, Berlin, Germany) with 9 mm round tooling, with curvature radius of 9mm (Figure 4). The compression speed was set to 30 rpm. Tablet target weight was set to 290 mg with target hardness of 70 N (Dr. Schleuniger Tablet Tester 8 M, Pharmatron AG, Thun, Switzerland). Obtained tablets had a height of 4.49 mm.

Characterization of tablets

HCQ tablets size parameters were determined using a digital scale caliper (Matrix Handels, Germany). Individual mass (n=10) of HCQ tablets was measured on an electronic balance (AX 204 Delta Range, Mettler Toledo, Switzerland).

Uniformity of mass

HCQ tablets weight and mass uniformity were determined according to the method provided by Eur. Pharm. 9.0, 2.9.40. In brief, 20 tablets were individually weighted on an electronic balance (KERN Balance ABT 220-5DNM; Kern & Sohn, Balingen, Germany). Weight of all of the selected tablets had a lower than 5% deviation from average.
Drug content and uniformity of dosage forms

Drug content of HCQ tablets (n=30) was evaluated by the HPLC-UV method proposed in USP29. Briefly, ten HCQ tablets were randomly selected from the sample of 30 tablets, independently dissolved in 200 mL of a methanol and water mixture (1:1). Dissolved solutions
were filtered (0.22 μm syringe filters) and further diluted 1:20 using HPLC mobile phase. For chromatographic separation by HPLC (UPLC Shimadzu Nexera 2), a C18 column was used (Waters Symetry C18, 5 μm, 4.6x100mm; Waters, Milford, USA). The column temperature was set to 25°C. Mobile phase was prepared according to USP29 (methanol : acetonitrile : water : phosphoric acid = 100 : 100 : 800 : 2). 96 mg of sodium-1-pentanesulfate was added to 1 L of the resulting solution and filtered. Drug concentrations were determined based on chromatographic peak areas according to USP29. A calibration curve was prepared by dissolving and diluting the USP analytical standard of HCQ in methanol and water (1:1 v/v). Tablet samples were prepared by dissolving each tablet in 200 mL of methanol water using an ultrasonic bath. The resulting solution was further diluted into mobile phase at a concentration of 0.05 mg/mL for injection.

**Disintegration of tablets**

The disintegration test was carried out using a Sotax DT2 apparatus (Sotax, Aesch, Switzerland). One HCQ tablet was introduced in each of the 6 baskets with a disc to prevent flotation (European Directorate for the Quality of Medicines, EDQM, 2012). Medium was distilled water.

**Friability**

Friability was tested using a TA200 apparatus (Erweka, Langen, Germany) using uncoated HCQ tablets subjected to 25 rpm and 100 revolutions according to EDQM, 2012. Friability was calculated for HCQ tablets according to Eq. (2):

\[
F = \frac{W_i - W_f}{W_i}
\]

Where \(W_i\) is the initial weight (mg) and \(W_f\) is the final weight (mg) after friability testing has been completed.
Dissolution studies

Drug release from HCQ tablets was measured using an USP II apparatus (Sotax AT7) at 37.0 ± 0.5°C. Dissolution conditions were according to USP 29. The dissolution buffers was distilled water. Samples were taken at one minute time intervals with a Sotax piston pump CY7 and were analyzed by UV–Vis spectrophotometry (Ultrospec 3100; Amersham Biosciences, Buckinghamshire, UK). The spectrophotometer was equipped with 1 mm quartz flow-through cuvettes.

Results and discussion

Results of identity tests

Hydroxychloroquine sulfate (HCQ, Figure 1) was acquired from an API manufacturer. A certificate of analysis was provided in compliance with USP/EP specifications. HCQ is a white or slightly yellowish crystalline powder. It is freely soluble in water and practically insoluble in ethanol (96%) and methylene chloride. According to USP 29 and EP 10, HCQ can be identified by Fourier Transform Infrared absorption spectroscopy (FTIR) using the neat solid on a diamond anvil (Figure 3). Characteristic peaks are given at 3202, 3088, 2970, 1612, 1444, 1365, 1342, 1248, 1215, 1082, 1024, 1006, 823, 604 and 589 cm⁻¹ (Figure 1). In addition to FTIR, the UV-HPLC assay described in USP 29 can be applied in to verify HCQ identity. The spectrophotometric scan of HCQ sulfate should show characteristic absorption maxima at 220 nm, 234 nm, 330 nm and 342 nm. HCQ should elute as a single peak. Whenever possible, nuclear magnetic resonance (NMR) spectroscopy and high-resolution mass spectrometry should be applied in addition to FTIR and UV-HPLC to confirm the molecular API identity. This method can be applied even when reference substances/spectra are not available. In the present study, NMR served as a mean to determine both purity and drug content.

Identity of HCQ was unambiguously determined by routine one- and two-dimensional NMR spectroscopy (¹H, ¹³C{¹H}, COSY, NOESY, HSQC, HMBC). The NMR spectra of HCQ sulfate (Figure 1) were assigned as follows: ¹H-NMR (D₂O, 298 K, 600.1 MHz): δ= 1.24 (t, ³J=7.3 Hz, 3H, H21), 1.39 (d, ³J=5.2 Hz, 3H, H22), 1.78/1.83 (m, 2H, H13a, H13b), 1.82/1.84 (m, 2H, H14a, H14b), 3.21/3.23 (m, 2H, H15a, H15b), 3.24 (m, 2H, H20), 3.26 (m, 2H, H20), 3.26 (m, 2H, H20), 3.26 (m, 2H, H17), 3.85 (t, ³J=5.2 Hz,
Identical NMR spectra of the pure API and the final tablet do not only demonstrate unambiguously the identity of the API, but also its stability during the entire formulation process. Purity of the API was > 99% as determined by liquid chromatography in agreement with the manufacturer’s certificate of analysis (Supplementary Figure 3).

NMR is also a valid method to confirm the absence of impurities listed in the EP for HCQ. The EP lists the following chemical impurities related to HCQ: mixture of diastereoisomers of 4-[(7-chloroquinolin-4-yl)amino]-N-ethyl-N-(hydroxyethyl)pentan-1-amine N-oxide; 2-[[4RS]-4-[(7-chloroquinolin-4-yl)amino]pentyl]- (ethyl)amino]ethyl hydrogen sulfate; 2-[[4RS]-4-[(7-chloroquinolin-4-yl)amino]pentyl]- amino]ethan-1-ol, D.) D. (4RS)-N4-(7-chloroquinolin-4-yl)-N1-ethylpentane-1,4- diamine; (4RS)-4-[(7-chloroquinolin-4-yl)amino]pentan-1-ol; 7-chloro-4-[(2RS)-2-methylpyrrolidin-1-yl]quinolone; 4,7-dichloroquinoline. As determined by quantitative NMR, the level of impurities was below the tolerated level described in the EP. Furthermore, NMR confirmed an acceptable level of residual solvents, such as methanol and ethanol (< 0.2% (w/w)).

High resolution electro-spray ionization mass spectrometry (HR-ESI-MS) was performed to corroborate the molecular formula with respect to atoms that are not easily detectable by NMR as e.g. chlorine, nitrogen and oxygen. Pure API and finely powdered tablet both were in agreement with the net formula for the cation of HCQ sulfate. Deviation between theoretical and measured values was less than 2 ppm: (m/z) calculated for C_{18}H_{27}ClN_{3}O^{+} of 336.1837 was in agreement with measured 336.1840 [M+H]^{+} (pure API) and 336.1843 [M+H]^{+} (tablet) (Figure S4).
**Figure 3. Spectroscopic analysis of HCQ tablets.** A) UV Absorption spectrum of HCQ with characteristic absorption peaks B) FT-IR spectrum of Hydroxychloroquine. C) $^1$H NMR (600 MHz, in D$_2$O) spectrum of HCQ. D) $^{13}$C NMR (151 MHz, in D$_2$O) spectrum of HCQ. Detailed two-dimensional NMR spectra (COSY, NOESY, HSQC, HMBC) are provided as supplementary information.

**Preparation of tablets**

The currently available formulations of HCQ (Plaquenil®) comes in a film coted immediate release tablet of 155 mg HCQ base (200 mg salt). According to the specification, excipients used in the formulation include lactose monohydrate, maize starch, magnesium stearate, polyvidone and Opadry OY-L-28900 (containing hypromellose, macrogol 4000, titanium dioxide (E171), lactose). Total parameters of the tablets are 293 mg and approximately 270 mm$^3$. The protective film coating of the tablet is not only protecting the tablet’s core but also masks the bitter taste of the API and facilitates swallowing of the tablet. The Plaquenil®
formulation itself is an immediate release dosage form with greater than 70% (w/w) drug load. The compatibility and compressibility of such formulations with concentrations of an API greater than the percolation thresholds are governed by the physico-chemical and mechanical properties of the drug substance. The same concept applies equally to powders’ behavior during high shear granulation process, which is a critical unit operation for this composition (11).

During wet granulation, the temperature of the powder bulk was gradually increasing. The reason for this is formation of liquid bridges between solid particles, which provide a closer contact between the solid formulation components, therefore increase inter-granular friction. Further transition of liquid bridge geometries towards funicular stage shifts the process to the state of a stable equilibrium between disruption and creation of liquid bridges, and as a consequence, towards formation of a uniform granular composition.

The granulation process was followed by drying of green granules in a tray dryer until granules’ residual moisture content reaches 1.5% (w/w). Dried granulate has formed weak slugs, those were passed through a 1.25mm sieve to obtain uniform granules with excellent flowability properties (6 g/second flow through an orifice according to Eur. Pharm. 9.0, 2.9.16).

The dried and sieved granulate was first mixed with disintegrant, followed by sequential blending with glidant and lubricant powders. Blending with a glidant prior to addition of a lubricant improved flowability and tablet weight uniformity at the cost of some possible increase in hydrophobic properties of the powder mixture (12). The latter was considered as minor factor due to good water solubility of the main formulation component, i.e., the HCQ sulphate.

Final powder blend was compressed into 9 mm concave tablets with 9 mm tablet cap radius of curvature. During tableting it was noticed that granules are susceptible to over-compression manifested as minor capping and decrease in tablet hardness. Tablet compaction was carried out in a non-instrumented tableting press, therefore identification of exact desired pressure range remains an open task (Figure 4).
Characterization of HCQ tablets
Manufactured tablets were characterized according to corresponding methods in USP 29 and EP 10. Tablet parameters such as tablet weight, diameter, height, hardness, friability were 299 ± 2 mg, 9 mm, 3.7 mm, 72.8 ± 11N, 0.1% (w/w), respectively. The weight and dimensions of our manufactured HCQ tablets are comparable to the commercial HCQ formulation, i.e. Plaquenil®.

Drug content and content uniformity
The measured HCQ dose per tablet showed an average drug content of 98.8 ± 5 % of the target dose. This is in line with requirements of the Eur. Pharm 9.0, 2.9.6.

Dissolution and disintegration studies
Dissolution profiles of Plaquenil® and our drug formulation were comparable (Figure 5). Both formulations release approximately 70% of drug within 30 minutes and more than 90% within 60 minutes. Requirements set forth in USP 29 are thus fulfilled. Drug release of our tablets is slightly slower as compared to the marketed formulation. However, our tablets release drug
in a more coherent manner as compared to Plaquenil® tablets. With regard to the results of the disintegration tests, both originator and our uncoated HCQ tablets disintegrated in less than 15 minutes, fulfilling the requirement for immediate release.

![Graphs showing drug release and disintegration time](image)

**Figure 5. Dissolution and disintegration of HCQ tablets.** A) Drug release (n=6) (left) and disintegration time of n=6 HCQ tablets. B) Drug release (n=6) (left) and disintegration time of n=3 Plaquenil® tablets. The dotted reference line indicates 70% of released drug content.
Conclusion

The COVID-19 pandemic has exposed the fragility of the global drug manufacturing and distribution system. This situation was of concern to patients suffering from pre-existing diseases, which were confronted with acute drug shortages for HCQ. In addition, developing countries had to face increasing costs for a WHO listed essential medicine against malaria. We therefore provide non-proprietary protocols covering analytical procedures and manufacturing of a HCQ generic. End users are invited to freely use, share, and modify our protocols. Our oral dosage form for HCQ was prepared using a cost-effective formulation strategy, readily available excipients, and a low number of units of operation. This should make our protocols adaptable to small- as well as large-scale manufacturing. Tablets are not coated. This reduces production costs and allows patients with swallowing difficulties to suspend crushed tablets in liquid containing, if necessary, taste masking components (13). In vitro profiling demonstrates close similarity of our generic drug formulation to FDA approved Plaquinil®. Considering recent FDA recommendations, it should be possible to apply for a bioequivalence waiver for immediate release formulations.

Acknowledgements

We are most grateful to Dr. M. Pfeffer and to P. Rieder (University of Basel) for performing the HR-ESI-MS spectrometry. We thank M. Nowak, P. Tschopp, A. Goeth and L. Soeren (Glatt AG, Binzen, Germany) for providing pharmaceutical excipients as a gift. We appreciate the help of Dr. S. Deuster with regulatory questions.
References


Figure S2. NMR analysis of HCQ. $^1$H NMR spectrum of HCQ before tableting (left panel) and after tableting (right panel).

Figure S3. UPLC elution profile of HCQ.
Figure S4. HR-ESI-MS spectra of HCQ.
Figure S5. HR-ESI-MS spectra of the HCQ tablet formulation.